| __timestamp | CRISPR Therapeutics AG | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 5758000 |
| Thursday, January 1, 2015 | 12573000 | 8423000 |
| Friday, January 1, 2016 | 42238000 | 11986000 |
| Sunday, January 1, 2017 | 69800000 | 15215000 |
| Monday, January 1, 2018 | 113773000 | 15356000 |
| Tuesday, January 1, 2019 | 179362000 | 16660000 |
| Wednesday, January 1, 2020 | 269407000 | 52459000 |
| Friday, January 1, 2021 | 17953000 | 75061000 |
| Saturday, January 1, 2022 | 110250000 | 87221000 |
| Sunday, January 1, 2023 | 130250000 | 83779000 |
| Monday, January 1, 2024 | -2314000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue trends for CRISPR Therapeutics AG and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, CRISPR Therapeutics AG experienced a staggering increase in its cost of revenue, peaking in 2020 with a 17-fold rise from its 2014 figures. This reflects the company's aggressive expansion and investment in cutting-edge gene-editing technologies. In contrast, Supernus Pharmaceuticals, Inc. showed a more stable growth pattern, with its cost of revenue increasing by approximately 14% annually, highlighting its steady market presence in the pharmaceutical sector. The data reveals how these companies navigate their financial landscapes, offering insights into their strategic priorities and market positioning.
Johnson & Johnson vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: AbbVie Inc. and CRISPR Therapeutics AG
Cost of Revenue: Key Insights for Pfizer Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: GSK plc vs CRISPR Therapeutics AG
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Exelixis, Inc. and CRISPR Therapeutics AG
Analyzing Cost of Revenue: Cytokinetics, Incorporated and CRISPR Therapeutics AG
Ionis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Alkermes plc vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Alkermes plc vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses